Views & Analysis | Perspectives on pharma industry issues

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Articles

Executive perspectives: Deepak Khanna

Paul Tunnah speaks with Deepak Khanna, Managing Director at MSD, about his recent appointment as President of the ABPI and the unique experience he brings to the role. Good health is something most people take for granted, but behind-the-scenes, the pharmaceutical industry has played, and continues to play...

Articles

What about the clinical research sites in Latin America?

Valentina Jaramillo provides an overview of the current environment of clinical research sites in Latin America. There have been discussions for a while now on the importance of developing countries in clinical research and I think it is pretty clear by now that all developing...

Articles

Why pharma clinical development must go beyond its means

Chris Fidyk takes a look at the history of the pharmaceutical industry, with regards to clinical trials legislation and how it has evolved over the years. As the American healthcare system marches slowly, but steadily, away from its fee-for-service roots towards a fee-for-value future...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Digital